Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSV Vaccination in Inflammatory Rheumatic Diseases
2024-518191-31-00Phase 4Authorised
- Sponsor
- Region Skåne
- Start
- Jul 2025
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of GSK3003899A and RSVpreF vaccine in respiratory syncytial virus disease (RSV) (2 arms), sponsored by Region Skåne. Primary endpoint: Antibody response (RSVpreF-specific IgG fold-change). Planned start Jul 2025; status: authorised.
02
Drugs
GSK3003899ARSVpreF vaccine
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2024-518191-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518191-31-00.